Interview with Patricia Lanssiers, Managing Director, Eli Lilly BeLux
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
Address: Rue de lEtuve 52 bte 1 1000 Brussels Belgium
Tel: +32 (0)2 548 84 84
Web: http://www.lilly.be/Nitro/
Eli Lilly is a specialty pharmaceutical company entirely dedicated to innovation. Today, we are developing drugs in the first or best in class.
Our main task is to meet the needs of patients. To this end, we discover and design drugs at the forefront of their therapeutic area and we disseminate information on health, in order to solve health problems which are often difficult and complex.
Our research and development is mainly in the following therapeutic areas:
Oncology
Endocrinology
Central nervous system
Cardiovascular
Urology
Since 1969, Eli Lilly & Company has been investing in Belgium. Can you give our readers a brief overview of the company’s history here and highlight some of your most…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
During the COVID-19 pandemic and the multi-stakeholder collaboration needed to find solutions, AstraZeneca launched the Partnership for Health System Sustainability and Resilience (PHSSR) in collaboration with KPMG, the London School…
Erik Present outlines Healixia’s progress in the past three years as the association which brings together medical professionals from across the Belgian healthcare and life sciences ecosystem has grown. Present…
PharmaScan BeLux is a non-profit organization established by pharma.be and Medaxes with the objective to collect and share reliable data on medicines delivered by pharmaceutical companies and distributors to healthcare…
Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its…
Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million…
One year into his first country management assignment at Takeda Belgium, Michael Nesrallah reflects on his initial impressions of the Belgian pharma market as well as its similarities and differences…
Alexander Natz of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) casts his eye over the potential effects of the upcoming EU Pharmaceutical Legislation for small- and medium-sized enterprises in Europe.…
After a 25-year-long career at Roche, spent at local affiliates in Switzerland, Germany, and the Netherlands, as well as in global positions in Switzerland and the US, Marie-José Borst took…
With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that…
Belgium’s drug reimbursement system has become increasingly lengthy and complex, compromising patient access to innovative medicines. The roadmap recently presented by the Minister of Health and the Belgian National Institute…
See our Cookie Privacy Policy Here
